Cellectar Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CLRB | ATNM | PCSA | LTRN | HBP.TO | CNSY | |
|---|---|---|---|---|---|---|
| Market cap | 11.63M | 44.33M | 5.41M | 8.76M | 70.27M | 6.77M |
| P/E (TTM) | — | 3.9 | — | — | — | — |
| Forward P/E | -0.6 | -2.7 | -0.5 | -0.3 | -8.4 | -0.4 |
| Price/book | 0.3 | 1.5 | -17.0 | -2.3 | 4.8 | 1.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −64.14% | +4.48% | −77.18% | −82.53% | −54.68% | −90.37% |
| Today | −6.11% | +0.71% | −0.26% | −2.61% | 0.00% | −31.42% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CLRB news ›Cellectar Biosciences (CLRB) Set to Release Quarterly Earnings on Tuesday
Posted by Sarita Garza on Nov 4th, 2026 Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.57) EPS for the quarter,…
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Stock Has Consensus Target Price of $11.00
Posted by Mitch Edgeman on Oct 22nd, 2026 View Our Latest Report on CLRB Shares of NASDAQ CLRB opened at $1.28 on Thursday. The stock’s 50-day moving average is $2.07 and its two-hundred day moving average is $2.51. Cellectar Biosciences…
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months Initiation and site selections for…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com2
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.